Table 2.
Human rabies cases in the Caribbean: case frequency and availability of human rabies biologics for pre-and post-exposure prophylaxis reported in the survey.
| Location | Years since Last Reported Case * | Mean # Human Cases per Year * | Causative Variant of Last Human Case | Pre-Exposure Vaccination | Biologics Available for Post-Exposure Prophylaxis |
|---|---|---|---|---|---|
| Belize | >20 | 0 | Canine | Yes | vaccine |
| Cuba | 1–5 | 0–1 | Mongoose | Yes | vaccine and RIG |
| Dominican Republic | <1 | 0–1 | Canine | Yes | vaccine |
| French Guiana | 6–10 | 0–1 | Bat | Yes | vaccine and RIG |
| Grenada | >20 | 0 | Mongoose | Yes | vaccine and RIG |
| Guyana | n.c.r. | 0 | n.c.r. | Yes | vaccine |
| Haiti | <1 | 6–10 # | Canine | Yes | vaccine and RIG |
| Puerto Rico | 1–5 | 0–1 | Mongoose | Yes | vaccine and RIG |
| Suriname | 11–20 | 0–1 | Bat | Yes | vaccine |
| Trinidad | >20 | 0 | Bat | Yes | vaccine |
* as at June 2018; # sub-notification suspected; n.c.r.: no cases reported on survey; RIG: rabies immune globulin.